Trial Profile

Study of NEU-001 for Hirschsprung Disease

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 19 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Apr 2024 According to Neurenati Therapeutics media release, the company concludes the Quebec Government's investment of $1.38 million via its Impulsion PME program, for which Investissement Quebec acts as agent. With the addition of angel investors, this brings the total funding to $2.9 million needed for Neurenati to effectively advance NEU-001 toward clinical trials. The company expects to file clinical trial application at the end of 2025 in Canada and the United States.
05 Mar 2024 New trial record
29 Feb 2024 According to Neurenati Therapeutics media release, the company announced the successful closing of its seed funding round, securing 1.2 million $ from Genson Capital, on the 2024 Rare Disease Day. Neurenati continues to keep the seed round open, and additional funding is expected during 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com